Veradermics, Inc MANE
Veradermics, Inc (NYSE: MANE) is a dermatology drug developer. Its lead program, VDPHL01, is in Phase 3 for Pattern hair loss (male and female). Its next catalyst on record is VDPHL01: Veradermics anticipates announcing data from Part B of Study '302' later this year. (H2 2026).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: VDPHL01 — Veradermics anticipates announcing data from Part B of Study '302' later this year. (H2 2026). 3 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| VDPHL01 - male Phase 3 (536 pts, fully enrolled) and male Phase 2/3 Study 302 (519 pts; positive topline April 2026) | Pattern hair loss, men | small molecule | Phase 3 |
| VDPHL01 - female Phase 2/3 Study 306 (552 pts target; enrollment complete) | Pattern hair loss, women | small molecule | Phase 3 |
| VDPHL01 - Phase 2 Study 207 (open label, men and women; positive topline July 2026) | Pattern hair loss | small molecule | Phase 2 |
Recent results and decisions
- Oct 19, 2026met Phase 3 Study 304 met all primary and secondary endpoints: non-vellus TAHC +28.6 (QD) and +36.4 (BID) hairs/cm2 vs +6.6 placebo at Month 6, p<0.0001; PRO improved/much improved 55.7%/68.7% vs 15.0%.
Participants achieved an average increase in non-vellus hair count of 28.6 hairs/cm² (p<0.0001) and 36.4 hairs/cm² (p<0.0001) in once-daily and twice-daily VDPHL01 treatment arms, respectively.
Filing - Aug 11, 2026completed enrollment Enrollment completed in Phase 2/3 Study 306 (556 women with female pattern hair loss).
Veradermics has completed enrollment of Study ‘306’, a Phase 2/3 multi-center, randomized, double-blind, placebo-controlled study evaluating the safety and efficacy of VDPHL01 at two dose regimens (4.5 mg once-daily and twice-daily) over 52 weeks in 556 female participants with mild-to-moderate patt
Filing - Jul 15, 2026positive Open-label Phase 2 Study 207 in women: non-vellus TAHC +22.7 (QD) and +23.3 (BID) hairs/cm2 at Month 6; 88.9%/90.0% reported improved or much improved; no treatment-related SAEs.
Participants achieved an average increase in non-vellus hair count of 22.7 hairs/cm² and 23.3 hairs/ cm² in once daily and twice daily VDPHL01 treatment arms, respectively.
Filing
1 more on record.
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 dermatology companies
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.